Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.Shaan Dudani, Daniel Yick Chin Heng, Lori Wood et al.|Journal of Clinical Oncology|2020Cited by 11
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Jeffrey Graham et al.|Journal of Clinical Oncology|2019Cited by 5
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Jeffrey Graham et al.|Journal of Clinical Oncology|2019Cited by 1